Nonagen Bioscience

Nonagen Bioscience is a private, pre-revenue diagnostics company founded in 2011 and headquartered in San Diego, California. The company is developing a multiplex protein immunoassay platform, with its lead candidate, Oncuria®, targeting bladder cancer for detection, recurrence monitoring, and therapy response prediction. As a physician-led organization, Nonagen's mission is to reduce the global burden of cancer by providing innovative diagnostic tools to improve clinical decision-making and patient outcomes.

Multiplex protein immunoassay platform for simultaneous measurement of multiple biomarkers from a single sample.

The bladder cancer diagnostic space is competitive, with other companies developing urine-based biomarker tests (e.g., NMP22, UroVysion) and new liquid biopsy assays using genomic or other molecular signatures. Nonagen's multiplex protein immunoassay approach must demonstrate superior clinical utility to gain market share.